MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company presented its latest advances in AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody development platform at Booth #44.
AI-Enabled Discovery of Highly Selective CLDN18.2 Antibodies
As part of the scientific program, Tsingke presented an AI-enabled workflow for discovering therapeutic antibodies targeting Claudin 18.2 (CLDN18.2), an emerging target for gastric cancer and other solid tumors.
The presentation demonstrated how AI-assisted sequence analysis and a proprietary screening strategy improve target specificity by reducing potential cross-reactivity with the closely related CLDN18.1 protein, a longstanding challenge in CLDN18.2 antibody development.
The resulting antibody candidates showed strong specificity and favorable developability, highlighting the potential of integrating AI with experimental validation to accelerate therapeutic antibody and antibody-drug conjugate (ADC) development.
End-to-End Antibody Development Capabilities
In addition to its scientific presentation, Tsingke showcased its integrated antibody development platform, covering multiple stages of biologics discovery and development, including:
- Antibody Discovery using hybridoma, single B-cell, and phage display technologies for the identification of high-affinity and highly specific antibodies.
- Antibody Engineering including antibody humanization, affinity maturation, and synthetic antibody library construction to accelerate therapeutic antibody optimization.
- Protein Expression supported by six expression systems and a rapid gene-to-protein workflow for applications including monoclonal antibodies, ADCs, AOCs, and in vitro diagnostics (IVD).
"AIS 2026 provided an excellent opportunity to share our latest work in AI-enabled antibody discovery and connect with researchers across the antibody community," said Chuanting Tan, Senior R&D Engineer at Tsingke. "As therapeutic antibody development becomes increasingly complex, integrating computational approaches with experimental validation can help researchers identify and optimize promising candidates more efficiently. We will continue to enhance our discovery and development capabilities to support innovation in biologics research."
Building on these efforts, Tsingke will continue expanding its AI-enabled discovery platform and integrated biologics capabilities to help researchers accelerate projects from early target discovery through protein expression and characterization.
About Tsingke
Tsingke Biotech is a leading innovator in synthetic biology, with a mission to build "the world's great gene factory." Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality Tsynth® gene synthesis services. Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences.
For news and updates, follow Tsingke Biotech on LinkedIn.
Contact: market@tsingke.com.cn
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
Vermon Group opens a new chapter with the acquisition of Moduleus, the opening of TransducerWorks' new U.S. manufacturing facility, and the launch of a coordinated Group platform designed to move faster, deliver more, and stay close to customers.
TOURS, France, July 8, 2026 /PRNewswire/ -- Vermon Group, an international ultrasound technology company specializing in OEM solutions for the medical and industrial markets, today announced three strategic milestones that mark a new phase of growth. These include the acquisition of Moduleus, a specialist in OEM ultrasound subsystems; the opening of TransducerWorks' new 30,000 sq. ft. manufacturing facility in Pennsylvania; and the launch of Vermon Group as a unified platform bringing together the complementary expertise of its four entities.
To view the Multimedia News Release, please click:
https://www.multivu.com/vermon-group/9408751-en-vermon-launches-vermon-group-accelerating-its-growth-and-expanding-its-offerings
Together, these milestones reflect the Group's evolution from a recognized manufacturer of ultrasound probes and transducers to a broader OEM ultrasound solutions partner, capable of supporting customers across an expanding portion of the ultrasound value chain.
The acquisition of Moduleus is a key step in this strategy. By adding expertise in OEM ultrasound subsystems, Vermon Group extends its historical strengths in acoustic technologies to deliver more integrated solutions. Customers now benefit from a single partner able to support projects ranging from high-performance transducers to OEM subsystems, helping simplify development and accelerate innovation.
The new TransducerWorks facility further strengthens the Group's U.S. manufacturing footprint. Four times larger than the previous site, it features ISO 7 and ISO 8 cleanrooms, an integrated machine shop, while tripling production capacity. This investment enhances Vermon Group's ability to support customers from early-stage development through high-volume manufacturing while providing greater responsiveness and proximity to North American OEMs.
By bringing together Vermon, Moduleus, TransducerWorks, and Vermon NDT under one coordinated Group platform, customers gain access to complementary expertise in acoustics, electronics, engineering, and industrial manufacturing through a single organization. This integrated approach enables OEMs to accelerate development, reduce complexity, and bring next-generation ultrasound technologies to market faster.
With more than 600 employees worldwide, over 130 dedicated R&D experts, more than 40 years of ultrasound expertise, and manufacturing operations in Europe and the United States, Vermon Group continues to strengthen its position as a trusted OEM partner for the next generation of medical and industrial ultrasound technologies.
About Vermon Group
Founded in 1984 in France, Vermon Group develops and manufactures high-performance ultrasound probes, transducers, OEM hardware electronics, subsystems, and integrated ultrasound solutions for medical and industrial applications. Through its four complementary entities, Vermon, TransducerWorks, Moduleus, and Vermon NDT, the Group combines acoustic expertise, electronics, and industrial manufacturing to help customers accelerate innovation from concept through high-volume production.
Contact:
Alexia AUBERGEON, a.aubergeon@vermon.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Vermon launches Vermon Group, accelerating its growth and expanding its offerings
